


## STUDY PROTOCOL

# Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol

Anouk W. M. A. Schaeffers<sup>1</sup>, Lot A. Devriese<sup>2</sup>, Carla H. van Gils<sup>3</sup>, Jan Willem Dankbaar<sup>4</sup>, Jens Voortman<sup>5</sup>, Jan Paul de Boer<sup>6</sup>, Marije Slingerland<sup>7</sup>, Mathijs P. Hendriks<sup>8</sup>, Ernst J. Smid<sup>9</sup>, Geert W. J. Frederix<sup>3</sup>, Remco de Bree<sup>1\*</sup>



**1** Department of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands, **2** Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands, **3** Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands, **4** Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands, **5** Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, location VUmc, Amsterdam, The Netherlands, **6** Department of Medical Oncology, Antoni van Leeuwenhoek, Amsterdam, The Netherlands, **7** Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands, **8** Department of Medical Oncology, Northwest Clinics, Alkmaar, The Netherlands, **9** Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands

\* [r.debree@umcutrecht.nl](mailto:r.debree@umcutrecht.nl)

## OPEN ACCESS

**Citation:** Schaeffers AWMA, Devriese LA, van Gils CH, Dankbaar JW, Voortman J, de Boer JP, et al. (2023) Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol. PLoS ONE 18(11): e0294147. <https://doi.org/10.1371/journal.pone.0294147>

**Editor:** Antonino Maniaci, University of Catania, ITALY

**Received:** July 31, 2023

**Accepted:** October 9, 2023

**Published:** November 27, 2023

**Peer Review History:** PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0294147>

**Copyright:** © 2023 Schaeffers et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## Abstract

Chemoradiotherapy with cisplatin in a triweekly regimen of 100 mg/m<sup>2</sup> body surface area, is used to treat locally advanced head and neck squamous cell carcinoma (HNSCC) with curative intent. Cisplatin dose limiting toxicity (CDLT) occurs often and impedes obtaining the planned cumulative cisplatin dose. A cumulative cisplatin dose of 200 mg/m<sup>2</sup> or more is warranted for better survival and locoregional control. Patients with a low skeletal muscle mass (SMM) have a three-fold higher risk of developing CDLT than patients with a normal SMM. SMM can be assessed through measurements on routinely performed diagnostic head and neck CT- or MRI-scans. A weekly regimen of 40 mg/m<sup>2</sup> body surface area cisplatin is proposed as a less toxic schedule, which possibly decreases the risk of developing CDLT and enables reaching a higher cumulative cisplatin dose. The aim of this multicenter randomized clinical trial (NL76533.041.21, registered in the Netherlands Trial Register) is to identify whether a regimen of weekly cisplatin increases compliance to the planned chemotherapy scheme in HNSCC patients with low SMM. The primary outcome is the difference in compliance rate, defined as absence of CDLT, between low SMM patients receiving either the weekly or triweekly regimen. Secondary outcomes consist of toxicities, the cumulative cisplatin dose, time to recurrence, incidence of recurrence at two years of follow-up, location of recurrence, 2-year overall, disease free and disease specific survival, quality of life, patient's experiences, and cost-effectiveness.

**Funding:** The Netherlands Organization for Health Research and Development (ZonMw), project number 10140021910002. The funders did not and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

## Introduction

Worldwide 900.000 new cases of head and neck squamous cell carcinoma (HNSCC) were estimated in 2018, which is approximately 5% of all new cancer cases [1]. Two-thirds of HNSCC patients present with advanced stage HNSCC. Cisplatin-based chemoradiotherapy (CCRT) is the preferred treatment for patients with unresectable or functionally irresectable HNSCC aiming for organ and function preservation. Next to CCRT, also other treatments that are possibly less invasive are currently available [2]. However, surgery will not be discussed in this article.

Cisplatin, dosed as 100 mg/m<sup>2</sup> body surface area (BSA), every three weeks for three cycles in combination with conventionally fractionated radiotherapy, consisting of 70 Gy in 35 fractions (five times a week) is the standard of care [3–9]. An alternative frequently used scheme is weekly cisplatin, dosed as 40 mg/m<sup>2</sup> BSA, for seven cycles with concurrent radiotherapy as described above. Cisplatin acts as a radiosensitizer. Locoregional control and survival improve significantly after treatment with CCRT compared to a single modality treatment with radiation [10–12]. CCRT is reserved only for patients who are deemed cisplatin fit, but nevertheless approximately one third of the patients is not able to complete the proposed triweekly regimen due to cisplatin dose limiting toxicity (CDLT). CDLT is caused by the detrimental side-effects of CCRT which are often comprised of nephrotoxicity, neurotoxicity, ototoxicity, leukopenia, mucositis and dermatitis [13–16].




HNSCC patients with low skeletal muscle mass (SMM) are more prone to developing CDLT [17–19]. In HNSCC patients SMM can be determined by delineating the cross-sectional muscle area (CSMA) by semi-automatic segmentation of the skeletal muscles at the third cervical vertebra (C3), using computed tomography (CT) or magnetic resonance imaging (MRI) scans. Subsequently CSMA at the (most frequently used) third lumbar vertebra (L3) can be calculated using a formula with age, weight, length, sex and the CSMA as variables. Then the lumbar skeletal muscle index (LSMI), the most often used measure for SMM, can be calculated by correcting for length [20–24]. The association between low SMM and CDLT might be explained by hydrophilic characteristics of cisplatin, causing distribution of cisplatin to fat-free body mass which is mainly composed of SMM [25]. Since cisplatin dosage is calculated using BSA, especially patients with low SMM but a large BSA receive relatively large quantities of cisplatin, possibly leading to a higher peak dosage. A higher peak dosage of cisplatin might consequently cause a higher rate of toxicities [26].

A weekly regimen of 40 mg/m<sup>2</sup> cisplatin for seven weeks might be an excellent alternative to the triweekly regimen in order to decrease rates of early treatment cessation, but studies show conflicting results [13, 15, 27–33]. Noronha et al. reported superiority of triweekly 100 mg/m<sup>2</sup> cisplatin compared to weekly cisplatin dosed as 30 mg/m<sup>2</sup> in cumulative two years loco-regional control [28]. Szturcz et al. found no statistical difference in survival between patients treated with triweekly 100 mg/m<sup>2</sup> cisplatin versus weekly 40 mg/m<sup>2</sup> cisplatin [13]. The European Society for Medical Oncology recommends the triweekly 100 mg/m<sup>2</sup> cisplatin regimen (level 1 evidence), over the weekly 40 mg/m<sup>2</sup> cisplatin regimen (level 2 evidence) [8]. Early discontinuation of therapy automatically leads to a reduced cumulative cisplatin dose, which is associated with lower overall survival. Therefore it can be anticipated that particularly patients with low SMM might benefit from weekly low dose cisplatin based concurrent CRT to achieve an adequate cumulative dose comparable to patients with normal SMM [10, 38, 40, 41].

## Materials and methods

The multicenter randomized clinical trial CISLOW is approved by the Medical Ethics Committee (METC), registered in the Netherlands Trial Register (NL76533.041.21), funded by The

Netherlands Organisation for Health Research and Development (ZonMw; 10140021910002) and conducted by five head and neck centers of the Dutch Head and Neck Society: University Medical Center Utrecht (UMCU), Amsterdam University Medical Centers location VUmc, Antoni van Leeuwenhoek, Leiden University Medical Center and Northwest Clinics. The SPIRIT schedule is shown in Fig 1. The starting date was January 2022. HNSCC patients who

|   | STUDY PERIOD    |                      |            |  |  |   |    |    |    |
|---|-----------------|----------------------|------------|--|--|---|----|----|----|
|   | Enrolment       | Before randomization | Allocation | Intervention<br>Cisplatin-based CRT <sup>a</sup>                                     | Follow-up (in months after end of CRT <sup>a</sup> ) |   |    |    |    |
| TIMEPOINT**   | -t <sub>1</sub> |                      | 0          | 0 – 7 weeks  | 3  | 6 | 12 | 18 | 24 |
| <b>ENROLMENT:</b>   |                 |                      |            |  |  |   |    |    |    |
| Eligibility screen  | X               |                      |            |  |  |   |    |    |    |
| Informed consent  | X               |                      |            |  |  |   |    |    |    |
| Allocation  |                 |                      | X          |  |  |   |    |    |    |
| <b>INTERVENTIONS:</b>   |                 |                      |            |  |  |   |    |    |    |
| Low SMM <sup>b</sup> weekly cisplatin                               |                 |                      |            |    |  |   |    |    |    |
| Low SMM <sup>b</sup> triweekly cisplatin                            |                 |                      |            |   |  |   |    |    |    |
| Normal SMM <sup>b</sup> local standard of care cisplatin            |                 |                      |            |  |  |   |    |    |    |
| <b>ASSESSMENTS:</b>   |                 |                      |            |  |  |   |    |    |    |
| Demographic data  | X               |                      |            |  |  |   |    |    |    |
| SMM <sup>b</sup> measurement  |                 | X                    |            |  |  | X |    | X  |    |
| Adverse events  |                 |                      |            | X  | X  | X | X  | X  | X  |
| Dose limiting toxicity  |                 |                      |            | X  |  |   |    |    |    |
| Quality of life questionnaires                                      |                 |                      | X          |  | X  | X | X  |    | X  |
| Semi-structured interviews in low SMM patients in UMCU <sup>c</sup> |                 |                      |            |  | X  |   |    |    |    |
| Oncologic outcomes (survival, recurrence)                           |                 |                      |            |  | X  | X | X  | X  | X  |

**Fig 1. SPIRIT schedule of enrollment, interventions and assessments.** a) CRT = Chemoradiotherapy, b) SMM = skeletal muscle mass, c) UMCU = University Medical Center Utrecht.

<https://doi.org/10.1371/journal.pone.0294147.g001>

**Table 1. Inclusion and exclusion criteria.**

| Inclusion criteria   | Exclusion criteria   |
|--|--|
| The patient is considered, eligible and planned for primary cisplatin-based chemoradiotherapy by treating physician; | The patient is mentally disabled and is unable to give informed consent;   |
| The patient is eighteen years of age or older;   | The patient has an absolute contraindication for triweekly cisplatin (100 mg/m <sup>2</sup> ) or is not cisplatin fit according to the treating physician; |
| The patient has sufficient understanding of Dutch and medical consequences to give informed consent.                 | The patient receives cisplatin in a non-primary intent or as induction treatment;  |
|  | The interval between the diagnostic scan used for skeletal muscle mass assessment and start of chemoradiotherapy is more than two months;                  |
|  | An accurate skeletal muscle mass measurement was not possible*.  |

\* Bilateral lymph node metastasis or artefacts at the level of the third cervical vertebra can compromise accurate skeletal muscle mass assessment. If imaging of the third lumbar vertebra is available and without artefacts, skeletal muscle mass can be assessed on this slice.

<https://doi.org/10.1371/journal.pone.0294147.t001>

are planned for CCRT, proposed by a multidisciplinary tumor board, and meet the criteria (as described in Table 1) will be asked to participate in this study.


### Assessment of skeletal muscle mass

SMM will be assessed on a routinely performed CT- or MRI-scan of the head and neck as shown in Figs 2 and 3. The SMM will be estimated based on measurement of the cross-sectional area of the sternocleidomastoid muscle and paravertebral muscles on the level of C3. Choosing a specific image slice at the level of C3 will be done by selecting the first slice showing both transverse processes and the entire vertebral arc when scrolling from caudal to cranial direction. Delineation of muscle tissue will be performed using the Slice-O-matic software v5.0 (Tomovision, Canada) [20]. If lymph node metastasis prohibits accurate delineation of either sternocleidomastoid muscle, the CSMA of the contralateral sternocleidomastoid muscle will be segmented and used to estimate the CSMA of the affected sternocleidomastoid muscle. In CT-scans muscle tissue will be identified semi-automatically using Hounsfield Unit range settings from -29 to +150, which is specific for muscle tissue [34]. In MRI-scans the muscle tissue will be manually segmented. The overall intraclass correlation coefficient for the CSMA obtained by CT and MRI has shown to be excellent (intraclass correlation coefficient 0.9,  $p < 0.01$ ), and can therefore be used interchangeably for measuring CSMA at the level of C3 [35]. Subsequently, the cervical skeletal muscle index (CSMI) will be calculated by dividing the CSMA at the level of C3 by the squared height of the patient. The LSMI will be calculated as following [20]:

$$\begin{aligned}
 &\text{CSMA at third lumbar vertebra (cm}^2\text{)} \\
 &= 27.304 + 1.363 * \text{CSMA at C3 (cm}^2\text{)} - 0.671 * \text{Age (years)} + 0.640 * \text{weight (kg)} \\
 &\quad + 26.442 * \text{Sex (female} \\
 &= 1, \text{ male} = 2)
 \end{aligned}$$

By dividing the CSMA at the level of the third lumbar vertebra (L3) by the squared height of the patient, the LSMI is calculated.

This method has been validated and appeared to be robust when comparing it to the common method measuring the muscle area at the level of the third lumbar vertebrae (L3) [22, 23, 34, 35].



**Fig 2. Cross sectional muscle area of cervical skeletal muscles in a patient without low skeletal muscle mass.** The right sternocleidomastoid muscle area is used twice to account for lymph node metastasis on the left side.


<https://doi.org/10.1371/journal.pone.0294147.g002>

### Intervention

Patients with low SMM ( $\text{LSMI} \leq 43.2 \text{ cm}^2/\text{m}^2$ ) will be randomized between weekly cisplatin ( $40 \text{ mg}/\text{m}^2$ ) and triweekly cisplatin ( $100 \text{ mg}/\text{m}^2$ ) and patients with a normal SMM ( $\text{LSMI} > 43.2 \text{ cm}^2/\text{m}^2$ ) will receive the local standard of care, which is triweekly cisplatin in the UMCU, Amsterdam University Medical Centers location VUmc, Leiden University Medical Center and Northwest Clinics and weekly cisplatin in Antoni van Leeuwenhoek, and will be observed [17, 36].

### Outcomes

The primary outcome of this study is the difference in compliance (defined as absence of CDLT) rate to the proposed cisplatin scheme between weekly cisplatin ( $40 \text{ mg}/\text{m}^2$ ) and triweekly cisplatin ( $100 \text{ mg}/\text{m}^2$ ) in patients with low SMM. CDLT for the triweekly schedule is defined as any toxicity resulting in a cisplatin dose-reduction of  $\geq 50\%$ , a postponement of treatment of  $\geq 4$  days or a definite termination of cisplatin after the first or second cycle of therapy, which is in line with the study of Wendrich et al. [17]. For weekly cisplatin regimens



**Fig 3.** Cross sectional muscle area of cervical skeletal muscles in a patient with low skeletal muscle mass.

<https://doi.org/10.1371/journal.pone.0294147.g003>

CDLT is defined as skipped cisplatin treatments or a definite termination of cisplatin before all scheduled cycles of therapy are given. Secondary outcomes of this study are treatment cumulative cisplatin dose, toxicities according the Common Toxicity Criteria Adverse Events version 5 during treatment and for a period of 24 months from the end of treatment, time to recurrence, incidence of recurrence at two years follow-up, location of recurrence (e.g., local, regional and distant recurrence), 2-years survival, quality of life measured by questionnaires (EORTC QLQ-C30, EORTCQLQ-H&N35, EQ-5D-5L) before and 3, 6, 12 and 24 months after CCRT, and a qualitative analysis using semi-structured interviews to assess patients' experiences towards the treatment schedule [14]. Cost-effectiveness analysis will be performed to compare triweekly and weekly cisplatin treatment in low SMM patients, with difference in costs, impact on quality of life and incremental cost-effectiveness ratio as outcomes. Electronic patient records will be checked during follow-up for two years. Follow-up will be according to Dutch guidelines [37]. Data management will be done using Castor software, taking privacy regulations into account. Patients' are insured by a trial subject insurance, the protocol has been checked by the Medical Research Ethics Committee in Utrecht (number 21–329), serious adverse events will be reported to the Medical Research Ethics Committee conform protocol and an external monitor checks the study team repeatedly for correct protocol handling.

### Sample size calculation and statistical procedures

Sample size calculation is based on the following assumptions. For the control arm of patients with low SMM and a triweekly regimen we expect a compliance rate of 55.7%, as was observed



in the study of Wendrich et al. in a similar population [17]. In the intervention arm of patients with low SMM and weekly cisplatin, we expect a compliance rate of 86.3%. This proportion was observed in the study of Wendrich et al. for patients with normal SMM and triweekly cisplatin [17]. Our hypothesis is that this same compliance rate can be obtained by using weekly cisplatin in patients with low SMM. The sample size was calculated to be able to indicate the difference between 55.7% and 86.3% as statistically significant, using a two-sided alpha of 0.05 and a power of 85%. With an expected drop-out rate of 5% and a low SMM incidence rate of approximately 55%, 129 patients must be included [17]. Patients with low SMM are centrally randomized 1:1 for triweekly high dose or weekly low dose cisplatin. Allocation is performed by a central office on-site computer combined with allocations kept in a locked, unreadable computer file that investigators can assess only after the characteristics of an enrolled patients are entered. A stratified permuted-block procedure randomizes patients to the groups on a 1:1 ratio. Strata comprise center and tumor stage (UICC I-III and IV) [38]. Neither patients, investigators nor office personnel are blinded to the group chosen by the randomization procedure. Fisher's exact tests, Pearson Chi square tests, independent sample t-tests and Mann-Whitney U tests will be used to assess group differences. All analyses will be two-sided and  $p < 0.05$  is considered significant. Missing data will be handled using multiple imputation, if needed; we only expect few missing data to occur due to the nature and scale of the study.

## Results and discussion

Cisplatin is routinely used in the curative treatment of locally advanced HNSCC as a radiosensitizing agent. Among various proposed treatment schedules, differing in frequency, dose, and route of administration, there is level 1 evidence for significant improvement in locoregional control and overall survival achieved by triweekly high dose (three cycles of  $100\text{mg}/\text{m}^2$ ) intravenous cisplatin given concurrently with conventional external beam radiotherapy compared to radiotherapy alone [8]. Despite indisputable efficacy, high rates of severe acute and late adverse events remain of concern. In fact, due to unacceptable systemic and local toxicities, up to 40% of patients fail to comply to all three planned cycles of high-dose cisplatin, which decrease local control and overall survival (3-year overall survival from 72% to 52% in HPV-negative patients) in individual patients [13, 39]. Besides, severe late toxicity (which has been reported in up to 13% of patients) is of concern leading to permanent morbidity [13, 40].

A systematic review pointed out a significant association between total cisplatin dose and overall survival [41]. Also Spreafico et al. found in a pooled analysis of 659 patients with locally advanced HNSCC with HPV positive tumors a survival benefit with cisplatin above  $200\text{mg}/\text{m}^2$  [42]. In a systematic review Szturz et al. compared the standard, triweekly high dose (three cycles of  $100\text{mg}/\text{m}^2$ ) cisplatin, and its alternative, weekly low dose (seven cycles of  $40\text{mg}/\text{m}^2$ ) cisplatin with concurrent radiation in locally advanced HNSCC. They found that, although treatment adherence was higher in the weekly schedule (88%) compared to the triweekly schedule (71%;  $p = 0.0017$ ), no statistical difference in survival was observed for the total population [13]. Although Jacinto et al. also concluded in a systematic review that triweekly cisplatin schedule should remain the standard of care for locally advanced HNSCC, they suggest a specific subset of not yet identified patients in whom weekly concurrent cisplatin is more appropriate to achieve a higher cumulative cisplatin dose [43].

Across cancer types, patients with a low SMM have a significantly higher risk of severe toxicity (Odds ratio (OR) 2.19–4.08) and dose-limiting toxicity (OR 2.24–2.48) compared to patients without low SMM [44, 45]. Patients with HNSCC and a low SMM show a higher risk CDLT. In a retrospective study, Wendrich et al. were the first to show an association between low SMM and the occurrence of CDLT in patients with HNSCC treated with triweekly

cisplatin-based CCRT. CDLT was defined as any toxicity resulting in a chemotherapy dose-reduction of  $\geq 50\%$ , a postponement of treatment of  $\geq 4$  days or a definite termination of chemotherapy after the first or second cycle of therapy. Of 112 patients included, 30.4% experienced CDLT. The SMM was estimated based on the same validated method we use in the CISLOW study [20, 23]. The optimal cut-off value for low SMM as a predictor of CDLT was  $\leq 43.2 \text{ cm}^2/\text{m}^2$ . Using this cut-off, 54.5% patients had low SMM. Patients with low SMM experienced CDLT more frequently than patients with normal SMM (44.3% vs. 13.7%,  $p < 0.001$ ) and received a higher dose of chemotherapy per kg lean body mass (estimated from SMM,  $p = 0.044$ ). Low SMM was independently inversely associated with CDLT (OR 0.93, 95%CI: 0.88–0.98) and patients experiencing CDLT showed shorter overall survival rates than patients who did not experience CDLT (mean 36.6 vs. 54.2 months,  $p = 0.038$ ) [17]. Recently, this study was enlarged ( $n = 343$ ), including patients whom were treated in a period of 10 years.

In line with the results from Wendrich et al., patients with low SMM prior CCRT were more likely to develop CDLT compared to patients without low SMM at diagnosis (51.8% vs. 36.8%,  $p < 0.01$ ) [17, 46]. These findings were confirmed by Bril et al. in a cohort of 153 HNSCC patients treated by chemoradiotherapy with triweekly high dose cisplatin in AvL. Of the 153 included patients 84 had low SMM (54.9%) defined as low CSMA at level C3 based on a cut-off value of  $10.7 \text{ cm}^2$  for women and  $13.1 \text{ cm}^2$  for men [18]. CDLT was defined as any toxicity leading to a cumulative cisplatin dose less than  $200 \text{ mg}/\text{m}^2$ . In total 37 (24.2%) patients experienced CDLT, and patients with low SMM experienced significantly more CDLT compared to patients without low SMM (33.7% vs. 10.9%,  $p = 0.001$ ), which is in line with other studies [18, 19, 47, 48]. Low SMM (HR 3.6, 95% CI 1.5–8.7,  $p = 0.004$ ) and an estimated glomerular filtration rate of 60–70 mL/min (HR 4.2, 95% CI 1.4–12.7,  $p = 0.012$ ) were independent predictors for CDLT in multivariate analysis. Moreover a significant lower OS was observed in patients who experienced CDLT compared to patients who did not experience CDLT (26.3 vs. 40.7 months,  $p = 0.003$ ) [18]. Although these studies showed that HNSCC patients with low SMM have a higher risk of CDLT, the results are difficult to compare because the definitions of CDLT and low SMM vary [18, 46].

In the CISLOW study, we use the same CDLT definition and cut-off point for low SMM as Wendrich et al. did since they performed their study in the same type of population [17]. Moreover, this definition takes the importance of the cumulative cisplatin dose into account. There remains some controversy about the optimal cut-off to define a low SMM and most are not validated in the HNSCC population. Often used cut-off values used are defined by Prado et al. and Martin et al. but these studies are executed in patients with lung or gastrointestinal malignancies and SMM is assessed at the level of L3 instead of C3 [25, 49]. Also in HNSCC studies different cut-off values are found when addressing different calculating methods or outcome values: for example Zwart et al. defined different cut-off points for different kinds of adverse events and Chargin et al. proposed to define low SMM based on the mean minus two standard-deviations, after grouping based on gender and BMI [50, 51]. Since Wendrich et al. specifically created a cut-off point for patients with HNSCC receiving chemoradiotherapy in the Netherlands, based on CDLT, using their cut-off point in our study with the same population is plausible [17]. In the CISLOW study we have chosen to stratify for the probably most important factors center and tumor stage. As HPV status is enclosed in the tumor stage, this will imply stratification for HPV status as well.

SMM assessment will be performed on CT- or MRI-scans, depending on availability. The whole body total skeletal muscle volume is often approached by assessing the CSMA at the level of L3 using a CT-scan and adjusting this for patient's height leading to the skeletal muscle index [24, 25]. In the diagnostic work up for HNSCC an abdominal scan is not standard of care, but Swartz et al. created a method to assess SMM on the level of C3, with a good



correlation ( $r = 0.785$ ) [20]. This was validated by Bril et al. and multiple studies showed excellent intra-observer and inter-observer agreement, even when using slightly different formulas [20, 23, 52–55]. Sometimes no CT-scan but an MRI-scan is made in the diagnostic work-up. Since there is a strong correlation between the CSMA measured at the level of C3 using a CT- and MRI-scan (intraclass correlation coefficient 0.9,  $p < 0.01$ ) and an excellent intra-observer agreement was found, we find it justifiable to use CT-scans or MRI-scans interchangeably in assessing SMM [22, 35, 53, 56].

In short, CDLT is common during CCRT in patients with HSNCC and consequently leads to a lower cumulative dosage of cisplatin which subsequently can affect survival [10, 17–19]. A solution to decrease the occurrence of CDLT while maintaining adequate cisplatin levels is warranted. By selecting a subgroup of patients that are especially prone to CDLT, namely patients with low SMM, and randomizing these patients between the triweekly and a the weekly regimen of cisplatin, we believe we can investigate whether the weekly regimen might be this solution. The results of this trial can lead to a change in guidelines for cisplatin treatment, might improve our understanding of the effect of SMM on CDLT and enhance personalized treatment in patients with HNSCC.

## Conclusions

Low SMM is predictive for CDLT in HNSCC patients receiving triweekly cisplatin in combination with radiotherapy with curative intent. Weekly cisplatin dosed as  $40 \text{ mg/m}^2$  BSA seems less toxic and is potentially non-inferior in comparison to triweekly cisplatin dosed as  $100 \text{ mg/m}^2$ . The aim of the CISLOW-study is to investigate whether the compliance of HNSCC patients with low SMM to cisplatin treatment as part of concurrent chemoradiation can be improved by using a weekly cisplatin regimen as high as HNSCC patients without a low SMM receiving a triweekly cisplatin regimen.

## Supporting information

**S1 Checklist. SPIRIT checklist.**

(DOCX)

**S2 Checklist. STROBE statement—checklist of items that should be included in reports of observational studies.**

(DOCX)

**S1 File. Informed consent materials in Dutch.**

(PDF)

**S2 File. Monitoring plan.**

(PDF)

**S3 File. Data management plan.**

(PDF)

**S4 File.**

(PDF)

## Author Contributions

**Conceptualization:** Anouk W. M. A. Schaeffers, Lot A. Devriese, Carla H. van Gils, Geert W. J. Frederix, Remco de Bree.

**Funding acquisition:** Remco de Bree.

**Investigation:** Anouk W. M. A. Schaeffers.

**Methodology:** Anouk W. M. A. Schaeffers, Lot A. Devriese, Carla H. van Gils, Geert W. J. Frederix, Remco de Bree.

**Project administration:** Anouk W. M. A. Schaeffers.

**Resources:** Anouk W. M. A. Schaeffers, Lot A. Devriese, Jan Willem Dankbaar, Jens Voortman, Jan Paul de Boer, Marije Slingerland, Mathijs P. Hendriks, Ernst J. Smid, Remco de Bree.

**Supervision:** Lot A. Devriese, Carla H. van Gils, Geert W. J. Frederix, Remco de Bree.

**Writing – original draft:** Anouk W. M. A. Schaeffers.

**Writing – review & editing:** Lot A. Devriese, Carla H. van Gils, Jan Willem Dankbaar, Jens Voortman, Jan Paul de Boer, Marije Slingerland, Mathijs P. Hendriks, Ernst J. Smid, Geert W. J. Frederix, Remco de Bree.

## References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018; 68(6):394–424. <https://doi.org/10.3322/caac.21492> PMID: 30207593
2. Di Luca M, Iannella G, Montevicchi F, Magliulo G, De Vito A, Cocuzza S, et al. Use of the transoral robotic surgery to treat patients with recurrent lingual tonsillitis. *Int J Med Robot*. 2020; 16(4):e2106. <https://doi.org/10.1002/rcs.2106> PMID: 32223059
3. Grégoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010; 21 (SUPPL. 5):184–6. <https://doi.org/10.1093/annonc/mdq185> PMID: 20555077
4. Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. *J Clin Oncol*. 2003; 21(1):92–8. <https://doi.org/10.1200/JCO.2003.01.008> PMID: 12506176
5. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. *N Engl J Med*. 2003 Nov; 349 (22):2091–8. <https://doi.org/10.1056/NEJMoa031317> PMID: 14645636
6. Sher DJ, Adelstein DJ, Bajaj GK, Brizel DM, Cohen EEW, Halthore A, et al. Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. *Pract Radiat Oncol*. 2017; 7(4):246–53. <https://doi.org/10.1016/j.prro.2017.02.002> PMID: 28428019
7. Oosting SF, Haddad RI. Best practice in systemic therapy for head and neck squamous cell carcinoma. *Front Oncol*. 2019; 9(AUG):1–9. <https://doi.org/10.3389/fonc.2019.00815> PMID: 31508372
8. Machiels JP, René Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann Oncol*. 2020; 31(11):1462–75.
9. Gebre-Medhin M, Brun E, Engström P, Cange HH, Hammarstedt-Nordenvall L, Reizenstein J, et al. ARTSCAN III: A randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer. *J Clin Oncol*. 2021; 39(1):38–47. <https://doi.org/10.1200/JCO.20.02072> PMID: 33052757
10. Pignon JP, Maître A le, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. *Radiother Oncol*. 2009; 92(1):4–14. <https://doi.org/10.1016/j.radonc.2009.04.014> PMID: 19446902
11. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, et al. Randomized Trial of Radiation Therapy Versus. *J Natl Cancer Inst*. 1999; 91(24):2081–6.
12. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. *Lancet*. 2000; 355(9208):949–55.

13. Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, et al. Low-dose vs. high-dose cisplatin: Lessons learned from 59 chemoradiotherapy trials in head and neck cancer. *Front Oncol*. 2019; 9(FEB). <https://doi.org/10.3389/fonc.2019.00086> PMID: 30847300
14. National Cancer Institute. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events Version 5.0. 2017.
15. Ghosh S, Rao PB, Kumar PR, Manam S. Concurrent chemoradiation with weekly cisplatin for the treatment of head and neck cancers: An institutional study on acute toxicity and response to treatment. *Asian Pacific J Cancer Prev*. 2015; 16(16):7331–5.
16. Rivelli TG, Mak MP, Martins RE, da Costa e Silva VT, de Castro G. Cisplatin based chemoradiation late toxicities in head and neck squamous cell carcinoma patients. *Discov Med*. 2015; 20(108):57–66.
17. Wendrich AW, Swartz JE, Bril SI, Wegner I, de Graeff A, Smid EJ, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. *Oral Oncol*. 2017 Aug; 71:26–33. <https://doi.org/10.1016/j.oraloncology.2017.05.012> PMID: 28688687
18. Bril SI, Al-Mamgani A, Chargin N, Remeijer P, Devriese LA, de Boer JP, et al. The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin. *Head Neck*. 2021 Oct 29;n/a(n/a). <https://doi.org/10.1002/hed.26919> PMID: 34713519
19. Nagpal P, Pruthi DS, Pandey M, Yadav A, Singh H. Impact of sarcopenia in locally advanced head and neck cancer treated with chemoradiation: An Indian tertiary care hospital experience. *Oral Oncol*. 2021 Oct; 121:105483. <https://doi.org/10.1016/j.oraloncology.2021.105483> PMID: 34403887
20. Swartz JE, Pothan AJ, Wegner I, Smid EJ, Swart KMA, de Bree R, et al. Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients. *Oral Oncol*. 2016; 62:28–33. <https://doi.org/10.1016/j.oraloncology.2016.09.006> PMID: 27865369
21. Ufuk F, Herek D, Yüksel D. Diagnosis of Sarcopenia in Head and Neck Computed Tomography: Cervical Muscle Mass as a Strong Indicator of Sarcopenia. *Clin Exp Otorhinolaryngol*. 2019 Aug; 12(3):317–24. <https://doi.org/10.21053/ceo.2018.01613> PMID: 30947498
22. Zwart AT, Becker JN, Lamers MJ, Dierckx RAJO, de Bock GH, Halmos GB, et al. Skeletal muscle mass and sarcopenia can be determined with 1.5-T and 3-T neck MRI scans, in the event that no neck CT scan is performed. *Eur Radiol*. 2020; <https://doi.org/10.1007/s00330-020-07440-1> PMID: 33219847
23. Bril SI, Wendrich AW, Swartz JE, Wegner I, Pameijer F, Smid EJ, et al. Interobserver agreement of skeletal muscle mass measurement on head and neck CT imaging at the level of the third cervical vertebra. *Eur Arch Oto-Rhino-Laryngology*. 2019; 276(4):1175–82. <https://doi.org/10.1007/s00405-019-05307-w> PMID: 30689037
24. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge M-P, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. *J Appl Physiol*. 2004 Dec; 97(6):2333–8. <https://doi.org/10.1152/jappphysiol.00744.2004> PMID: 15310748
25. Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. *Lancet Oncol*. 2008 Jul; 9(7):629–35. [https://doi.org/10.1016/S1470-2045\(08\)70153-0](https://doi.org/10.1016/S1470-2045(08)70153-0) PMID: 18539529
26. Chargin N, Molenaar-Kuijsten L, Huiskamp LFJ, Devriese LA, de Bree R, Huijtema ADR. The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA study. *Eur J Cancer*. 2021; <https://doi.org/10.1016/j.ejca.2021.10.010> PMID: 34810046
27. Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, et al. Preliminary results of Radiation Therapy Oncology Group 97–03: A randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. *J Clin Oncol*. 2004; 22(14):2856–64. <https://doi.org/10.1200/JCO.2004.12.012> PMID: 15254053
28. Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A, et al. Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. *J Clin Oncol*. 2018; 36(11):1064–72. <https://doi.org/10.1200/JCO.2017.74.9457> PMID: 29220295
29. Tsan D-L, Lin C-Y, Kang C-J, Huang S-F, Fan K-H, Liao C-T, et al. The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. *Radiat Oncol*. 2012 Dec; 7:215. <https://doi.org/10.1186/1748-717X-7-215> PMID: 23245290
30. Quon H, Leong T, Haselow R, Leipzig B, Cooper J, Forastiere A. Phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the

- head and neck: an intergroup trial of the Eastern Cooperative Oncology Group (E2382). *Int J Radiat Oncol Biol Phys*. 2011; 81(3):719–25. <https://doi.org/10.1016/j.ijrobp.2010.06.038> PMID: 20888709
31. Ho KF, Swindell R, Brammer C V. Dose intensity comparison between weekly and 3-weekly Cisplatin delivered concurrently with radical radiotherapy for head and neck cancer: A retrospective comparison from New Cross Hospital, Wolverhampton, UK. *Acta Oncol (Madr)*. 2008; 47(8):1513–8. <https://doi.org/10.1080/02841860701846160> PMID: 18607863
  32. Gupta T, Agarwal JP, Ghosh-Laskar S, Parikh PM, D'Cruz AK, Dinshaw KA. Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience. *Head Neck Oncol*. 2009 Jun; 1:17. <https://doi.org/10.1186/1758-3284-1-17> PMID: 19527507
  33. Otty Z, Skinner MB, Dass J, Collins M, Mooi J, Thuraisingam K, et al. Efficacy and tolerability of weekly low-dose cisplatin concurrent with radiotherapy in head and neck cancer patients. *Asia Pac J Clin Oncol*. 2011 Sep; 7(3):287–92. <https://doi.org/10.1111/j.1743-7563.2011.01405.x> PMID: 21884441
  34. Heymsfield SB, Wang Z, Baumgartner RN, Ross R. Human body composition: advances in models and methods. *Annu Rev Nutr*. 1997; 17:527–58. <https://doi.org/10.1146/annurev.nutr.17.1.527> PMID: 9240939
  35. Chargin N, Ansari E, Huiskamp LFJ, Bol G, de Bree R. Agreement between skeletal muscle mass measurements using computed tomography imaging and magnetic resonance imaging in head and neck cancer patients. *Oral Oncol*. 2019; 99:104341. <https://doi.org/10.1016/j.oraloncology.2019.06.022> PMID: 31253538
  36. Chargin N, Bril S, Emmelot-Vonk M, de Bree R. Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer. *Eur Arch Oto-Rhino-Laryngology*. 2019; 276(5):1475–86.
  37. Federatie Medische Specialisten. Richtlijn Hoofd-halstumoren, chemoradiatie en bioradiatie van hoofd-hals [Internet]. Richtlijndatabase. 2014 [cited 2022 Feb 11]. Available from: [https://richtlijndatabase.nl/richtlijn/hoofd-halstumoren/chemoradiatie\\_en\\_bioradiatie\\_van\\_hoofd-hals.html](https://richtlijndatabase.nl/richtlijn/hoofd-halstumoren/chemoradiatie_en_bioradiatie_van_hoofd-hals.html)
  38. Brierley J, Gospodarowicz M, Wittekind C. *TNM Classification of Malignant Tumours*. 8th ed. Oxford UK; Hoboken NJ: John Wiley & Sons, Inc; 2017.
  39. Szturcz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, et al. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. *Oncologist*. 2017 Sep; 22(9):1056–66. <https://doi.org/10.1634/theoncologist.2017-0015> PMID: 28533474
  40. Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys*. 2012 Dec; 84(5):1198–205. <https://doi.org/10.1016/j.ijrobp.2012.05.008> PMID: 22749632
  41. Strojjan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M, Bossi P, et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. *Head & neck*. 2016; 38 Suppl 1:E2151–8. <https://doi.org/10.1002/hed.24026> PMID: 25735803
  42. Spreafico A, Huang S, Xu W, Granata R, Liu C, Waldron J, et al. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. *Eur J Cancer*. 2016; 67:174. <https://doi.org/10.1016/j.ejca.2016.08.013> PMID: 27669504
  43. Jacinto JK, Co J, Mejia MB, Regala EE. The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta-analysis. *Br J Radiol*. 2017 Nov; 90(1079):20170442. <https://doi.org/10.1259/bjr.20170442> PMID: 29053029
  44. Huiskamp LFJ, Chargin N, Devriese LA, May AM, Huitema ADR, de Bree R. The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis. *J Clin Med*. 2020 Nov; 9(11). <https://doi.org/10.3390/jcm9113780> PMID: 33238530
  45. Surov A, Pech M, Gessner D, Mikusko M, Fischer T, Alter M, et al. Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis. *Clin Nutr*. 2021 Oct; 40(10):5298–310. <https://doi.org/10.1016/j.clnu.2021.08.023> PMID: 34536638
  46. Chargin N, Bashiri F, Wendrich AW, Smid EJ, de Jong PA, Huitema ADR, et al. Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer. *Eur Arch Oto-Rhino-Laryngology*. 2022; 279(7):3685–94. <https://doi.org/10.1007/s00405-021-07229-y> PMID: 35038029
  47. Huang X, Lv L-N, Zhao Y, Li L, Zhu X-D. Is skeletal muscle loss associated with chemoradiotherapy toxicity in nasopharyngeal carcinoma patients? A prospective study. *Clin Nutr*. 2021 Jan; 40(1):295–302. <https://doi.org/10.1016/j.clnu.2020.05.020> PMID: 32507513

48. Shodo R, Yamazaki K, Ueki Y, Takahashi T, Horii A. Sarcopenia predicts a poor treatment outcome in patients with head and neck squamous cell carcinoma receiving concurrent chemoradiotherapy. *Eur Arch oto-rhino-laryngology Off J Eur Fed Oto-Rhino-Laryngological Soc Affil with Ger Soc Oto-Rhino-Laryngology—Head Neck Surg.* 2021 Jun; 278(6):2001–9. <https://doi.org/10.1007/s00405-020-06273-4> PMID: 32772234
49. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. *J Clin Oncol Off J Am Soc Clin Oncol.* 2013 Apr; 31(12):1539–47. <https://doi.org/10.1200/JCO.2012.45.2722> PMID: 23530101
50. Zwart AT, Pörtzgen W, van Rijn-Dekker I, Sidorenkov GA, Dierckx RAJO, Steenbakkers RJHM, et al. Sex-Specific Cut-Off Values for Low Skeletal Muscle Mass to Identify Patients at Risk for Treatment-Related Adverse Events in Head and Neck Cancer. *J Clin Med.* 2022 Aug; 11(16). <https://doi.org/10.3390/jcm11164650> PMID: 36012884
51. Chargin N, Bril SI, Smid EJ, de Jong PA, de Bree R. Cut-off values for low skeletal muscle mass at the level of the third cervical vertebra (C3) in patients with head and neck cancer. *Quant Imaging Med Surg.* 2022 Jun; 12(6):3024–33. <https://doi.org/10.21037/qims-21-911> PMID: 35655816
52. Zwart AT, van der Hoorn A, van Ooijen PMA, Steenbakkers RJHM, de Bock GH, Halmos GB. CT-measured skeletal muscle mass used to assess frailty in patients with head and neck cancer. *J Cachexia Sarcopenia Muscle.* 2019 Oct 1; 10(5):1060–9. <https://doi.org/10.1002/jcsm.12443> PMID: 31134765
53. Bril SI, van Beers MA, Chargin N, Carrillo Minulina N, Smid EJ, Dankbaar JW, et al. Skeletal muscle mass at C3 is a strong predictor for skeletal muscle mass at L3 in sarcopenic and non-sarcopenic patients with head and neck cancer. Vol. 122, *Oral oncology.* England; 2021. p. 105558.
54. Jung AR, Roh J-L, Kim JS, Choi S-H, Nam SY, Kim SY. Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer. *Oral Oncol.* 2019; 95:95–9. <https://doi.org/10.1016/j.oraloncology.2019.06.009> PMID: 31345401
55. Lu X, Tian Y, Huang J, Li F, Shao T, Huang G, et al. Evaluating the prognosis of oral squamous cell carcinoma patients via L3 skeletal muscle index. *Oral Dis.* 2023 Nov 12; 29(3):923–32. <https://doi.org/10.1111/odi.14074> PMID: 34773352
56. de Bree R, van Beers MA, Schaeffers AWMA. Sarcopenia and its impact in head and neck cancer treatment. *Curr Opin Otolaryngol Head Neck Surg.* 2022 Apr; 30(2):87–93. <https://doi.org/10.1097/MOO.0000000000000792> PMID: 35255045